Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Medicine
Published in: BMC Medicine 1/2013

Open Access 01-12-2013 | Review

The sweet and sour of serological glycoprotein tumor biomarker quantification

Authors: Uros Kuzmanov, Hari Kosanam, Eleftherios P Diamandis

Published in: BMC Medicine | Issue 1/2013

Login to get access

Abstract

Aberrant and dysregulated protein glycosylation is a well-established event in the process of oncogenesis and cancer progression. Years of study on the glycobiology of cancer have been focused on the development of clinically viable diagnostic applications of this knowledge. However, for a number of reasons, there has been only sparse and varied success. The causes of this range from technical to biological issues that arise when studying protein glycosylation and attempting to apply it to practical applications. This review focuses on the pitfalls, advances, and future directions to be taken in the development of clinically applicable quantitative assays using glycan moieties from serum-based proteins as analytes. Topics covered include the development and progress of applications of lectins, mass spectrometry, and other technologies towards this purpose. Slowly but surely, novel applications of established and development of new technologies will eventually provide us with the tools to reach the ultimate goal of quantification of the full scope of heterogeneity associated with the glycosylation of biomarker candidate glycoproteins in a clinically applicable fashion.
Appendix
Available only for authorised users
Literature
1.
Cunningham S, Gerlach JQ, Kane M, Joshi L: Glyco-biosensors: Recent advances and applications for the detection of free and bound carbohydrates. Analyst. 2010, 135: 2471-2480. 10.1039/c0an00276c.PubMed
2.
Dalpathado DS, Desaire H: Glycopeptide analysis by mass spectrometry. Analyst. 2008, 133: 731-738. 10.1039/b713816d.PubMed
3.
Reinders J, Sickmann A: Modificomics: posttranslational modifications beyond protein phosphorylation and glycosylation. Biomol Eng. 2007, 24: 169-177. 10.1016/j.bioeng.2007.03.002.PubMed
4.
Walsh CT, Garneau-Tsodikova S, Gatto GJ: Protein posttranslational modifications: the chemistry of proteome diversifications. Angew Chem Int Ed Engl. 2005, 44: 7342-7372. 10.1002/anie.200501023.PubMed
5.
Crocker PR, Feizi T: Carbohydrate recognition systems: functional triads in cell-cell interactions. Curr Opin Struct Biol. 1996, 6: 679-691. 10.1016/S0959-440X(96)80036-4.PubMed
6.
Feizi T: Carbohydrate-mediated recognition systems in innate immunity. Immunol Rev. 2000, 173: 79-88. 10.1034/j.1600-065X.2000.917310.x.PubMed
7.
Gabius HJ, Siebert HC, Andre S, Jimenez-Barbero J, Rudiger H: Chemical biology of the sugar code. Chembiochem. 2004, 5: 740-764. 10.1002/cbic.200300753.PubMed
8.
Helenius A, Aebi M: Intracellular functions of N-linked glycans. Science. 2001, 291: 2364-2369. 10.1126/science.291.5512.2364.PubMed
9.
Karlsson KA: Meaning and therapeutic potential of microbial recognition of host glycoconjugates. Mol Microbiol. 1998, 29: 1-11. 10.1046/j.1365-2958.1998.00854.x.PubMed
10.
Apweiler R, Hermjakob H, Sharon N: On the frequency of protein glycosylation, as deduced from analysis of the SWISS-PROT database. Biochim Biophys Acta. 1999, 1473: 4-8. 10.1016/S0304-4165(99)00165-8.PubMed
11.
Cummings RD: The repertoire of glycan determinants in the human glycome. Mol Biosyst. 2009, 5: 1087-1104. 10.1039/b907931a.PubMed
12.
Schachter H, Freeze HH: Glycosylation diseases: quo vadis?. Biochim Biophys Acta. 2009, 1792: 925-930. 10.1016/j.bbadis.2008.11.002.PubMed
13.
Spiro RG: Protein glycosylation: nature, distribution, enzymatic formation, and disease implications of glycopeptide bonds. Glycobiology. 2002, 12: 43R-56R. 10.1093/glycob/12.4.43R.PubMed
14.
Meezan E, Wu HC, Black PH, Robbins PW: Comparative studies on the carbohydrate-containing membrane components of normal and virus-transformed mouse fibroblasts. II. Separation of glycoproteins and glycopeptides by sephadex chromatography. Biochemistry. 1969, 8: 2518-2524. 10.1021/bi00834a039.PubMed
15.
Wu HC, Meezan E, Black PH, Robbins PW: Comparative studies on the carbohydrate-containing membrane components of normal and virus-transformed mouse fibroblasts. I. Glucosamine-labeling patterns in 3T3, spontaneously transformed 3T3, and SV-40-transformed 3T3 cells. Biochemistry. 1969, 8: 2509-2517. 10.1021/bi00834a038.PubMed
16.
Brooks SA: Strategies for analysis of the glycosylation of proteins: current status and future perspectives. Mol Biotechnol. 2009, 43: 76-88. 10.1007/s12033-009-9184-6.PubMed
17.
Drake PM, Cho W, Li B, Prakobphol A, Johansen E, Anderson NL, Regnier FE, Gibson BW, Fisher SJ: Sweetening the pot: adding glycosylation to the biomarker discovery equation. Clin Chem. 2010, 56: 223-236. 10.1373/clinchem.2009.136333.PubMed
18.
Arnold JN, Saldova R, Hamid UM, Rudd PM: Evaluation of the serum N-linked glycome for the diagnosis of cancer and chronic inflammation. Proteomics. 2008, 8: 3284-3293. 10.1002/pmic.200800163.PubMed
19.
Dennis JW, Granovsky M, Warren CE: Glycoprotein glycosylation and cancer progression. Biochim Biophys Acta. 1999, 1473: 21-34. 10.1016/S0304-4165(99)00167-1.PubMed
20.
Dube DH, Bertozzi CR: Glycans in cancer and inflammation--potential for therapeutics and diagnostics. Nat Rev Drug Discov. 2005, 4: 477-488. 10.1038/nrd1751.PubMed
21.
Gorelik E, Galili U, Raz A: On the role of cell surface carbohydrates and their binding proteins (lectins) in tumor metastasis. Cancer Metastasis Rev. 2001, 20: 245-277. 10.1023/A:1015535427597.PubMed
22.
Hakomori S: Glycosylation defining cancer malignancy: new wine in an old bottle. Proc Natl Acad Sci USA. 2002, 99: 10231-10233. 10.1073/pnas.172380699.PubMedPubMedCentral
23.
Granovsky M, Fata J, Pawling J, Muller WJ, Khokha R, Dennis JW: Suppression of tumor growth and metastasis in Mgat5-deficient mice. Nat Med. 2000, 6: 306-312. 10.1038/73163.PubMed
24.
Guo HB, Lee I, Kamar M, Pierce M: N-acetylglucosaminyltransferase V expression levels regulate cadherin-associated homotypic cell-cell adhesion and intracellular signaling pathways. J Biol Chem. 2003, 278: 52412-52424. 10.1074/jbc.M308837200.PubMed
25.
Handerson T, Camp R, Harigopal M, Rimm D, Pawelek J: Beta1,6-branched oligosaccharides are increased in lymph node metastases and predict poor outcome in breast carcinoma. Clin Cancer Res. 2005, 11: 2969-2973. 10.1158/1078-0432.CCR-04-2211.PubMed
26.
Pinho SS, Reis CA, Paredes J, Magalhaes AM, Ferreira AC, Figueiredo J: The role of N-acetylglucosaminyltransferase III and V in the post-transcriptional modifications of E-cadherin. Hum Mol Genet. 2009, 18: 2599-2608. 10.1093/hmg/ddp194.PubMed
27.
Takahashi M, Kuroki Y, Ohtsubo K, Taniguchi N: Core fucose and bisecting GlcNAc, the direct modifiers of the N-glycan core: their functions and target proteins. Carbohydr Res. 2009, 344: 1387-1390. 10.1016/j.carres.2009.04.031.PubMed
28.
Burchell J, Poulsom R, Hanby A, Whitehouse C, Cooper L, Clausen H: An alpha2,3 sialyltransferase (ST3Gal I) is elevated in primary breast carcinomas. Glycobiology. 1999, 9: 1307-1311. 10.1093/glycob/9.12.1307.PubMed
29.
Meany D, Chan D: Aberrant glycosylation associated with enzymes as cancer biomarkers. Clinical Proteomics. 2011, 8: 7-10.1186/1559-0275-8-7.PubMedPubMedCentral
30.
Ogawa JI, Inoue H, Koide S: alpha-2,3-Sialyltransferase type 3N and alpha-1,3-fucosyltransferase type VII are related to sialyl Lewis(x) synthesis and patient survival from lung carcinoma. Cancer. 1997, 79: 1678-1685. 10.1002/(SICI)1097-0142(19970501)79:9<1678::AID-CNCR7>3.0.CO;2-8.PubMed
31.
Petretti T, Kemmner W, Schulze B, Schlag PM: Altered mRNA expression of glycosyltransferases in human colorectal carcinomas and liver metastases. Gut. 2000, 46: 359-366. 10.1136/gut.46.3.359.PubMedPubMedCentral
32.
Picco G, Julien S, Brockhausen I, Beatson R, Antonopoulos A, Haslam S: Over-expression of ST3Gal-I promotes mammary tumorigenesis. Glycobiology. 2010, 20: 1241-1250. 10.1093/glycob/cwq085.PubMedPubMedCentral
33.
Recchi MA, Hebbar M, Hornez L, Harduin-Lepers A, Peyrat JP, Delannoy P: Multiplex reverse transcription polymerase chain reaction assessment of sialyltransferase expression in human breast cancer. Cancer Res. 1998, 58: 4066-4070.PubMed
34.
Fukushima K, Satoh T, Baba S, Yamashita K: alpha1,2-Fucosylated and beta-N-acetylgalactosaminylated prostate-specific antigen as an efficient marker of prostatic cancer. Glycobiology. 2010, 20: 452-460. 10.1093/glycob/cwp197.PubMed
35.
Jankovic MM, Milutinovic BS: Glycoforms of CA125 antigen as a possible cancer marker. Cancer Biomark. 2008, 4: 35-42.PubMed
36.
Valmu L, Alfthan H, Hotakainen K, Birken S, Stenman UH: Site-specific glycan analysis of human chorionic gonadotropin beta-subunit from malignancies and pregnancy by liquid chromatography--electrospray mass spectrometry. Glycobiology. 2006, 16: 1207-1218. 10.1093/glycob/cwl034.PubMed
37.
Saeland E, Belo AI, Mongera S, van Die I, Meijer GA, van Kooyk Y: Differential glycosylation of MUC1 and CEACAM5 between normal mucosa and tumour tissue of colon cancer patients. Int J Cancer. 2012, 131: 117-128. 10.1002/ijc.26354.PubMed
38.
Narimatsu H, Sawaki H, Kuno A, Kaji H, Ito H, Ikehara Y: A strategy for discovery of cancer glyco-biomarkers in serum using newly developed technologies for glycoproteomics. FEBS J. 2010, 277: 95-105. 10.1111/j.1742-4658.2009.07430.x.PubMed
39.
Pan S, Chen R, Aebersold R, Brentnall TA: Mass spectrometry based glycoproteomics - from a proteomics perspective. Mol Cell Proteomics. 2011, 10.
40.
Hua S, An HJ: Glycoscience aids in biomarker discovery. BMB Rep. 2012, 45: 323-330. 10.5483/BMBRep.2012.45.6.132.PubMed
41.
Adamczyk B, Tharmalingam T, Rudd PM: Glycans as cancer biomarkers. Biochim Biophys Acta. 2011
42.
Goonetilleke KS, Siriwardena AK: Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol. 2007, 33: 266-270. 10.1016/j.ejso.2006.10.004.PubMed
43.
Donati M, Brancato G, Donati A: Clinical biomarkers in hepatocellular carcinoma (HCC). Front Biosci (Schol Ed). 2010, 2: 571-577.
44.
Li D, Mallory T, Satomura S: AFP-L3: a new generation of tumor marker for hepatocellular carcinoma. Clin Chim Acta. 2001, 313: 15-19. 10.1016/S0009-8981(01)00644-1.PubMed
45.
Gamblin DP, Scanlan EM, Davis BG: Glycoprotein synthesis: an update. Chem Rev. 2009, 109: 131-163. 10.1021/cr078291i.PubMed
46.
Peracaula R, Tabares G, Royle L, Harvey DJ, Dwek RA, Rudd PM, de Llorens R: Altered glycosylation pattern allows the distinction between prostate-specific antigen (PSA) from normal and tumor origins. Glycobiology. 2003, 13: 457-470. 10.1093/glycob/cwg041.PubMed
47.
Anderson NL, Anderson NG: The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics. 2002, 1: 845-867. 10.1074/mcp.R200007-MCP200.PubMed
48.
Sharon N, Lis H: History of lectins: from hemagglutinins to biological recognition molecules. Glycobiology. 2004, 14: 53R-62R. 10.1093/glycob/cwh122.PubMed
49.
Bies C, Lehr CM, Woodley JF: Lectin-mediated drug targeting: history and applications. Adv Drug Deliv Rev. 2004, 56: 425-435. 10.1016/j.addr.2003.10.030.PubMed
50.
Sharon N, Lis H: Lectins: cell-agglutinating and sugar-specific proteins. Science. 1972, 177: 949-959. 10.1126/science.177.4053.949.PubMed
51.
McCoy JP, Varani J, Goldstein IJ: Enzyme-linked lectin assay (ELLA): use of alkaline phosphatase-conjugated Griffonia simplicifolia B4 isolectin for the detection of alpha-D-galactopyranosyl end groups. Anal Biochem. 1983, 130: 437-444. 10.1016/0003-2697(83)90613-9.PubMed
52.
McCoy JP, Goldstein IJ, Varani J: A review of studies in our laboratory regarding ELLA methodology for the study of cell surface carbohydrates from tumors of varying metastatic potential. Tumour Biol. 1985, 6: 99-114.PubMed
53.
Reddi AL, Sankaranarayanan K, Arulraj HS, Devaraj N, Devaraj H: Enzyme-linked PNA lectin-binding assay of serum T-antigen in patients with SCC of the uterine cervix. Cancer Lett. 2000, 149: 207-211. 10.1016/S0304-3835(99)00363-8.PubMed
54.
Zhang SL, Liang YR, Li JL, Dai YR, Huang D: Preliminary studies of serum glycoconjugates in patients with cancer using the enzyme-linked lectin assay. Cancer Biochem Biophys. 1990, 11: 211-216.PubMed
55.
Graham K, Keller K, Ezzell J, Doyle R: Enzyme-linked lectinosorbent assay (ELLA) for detecting Bacillus anthracis. Eur J Clin Microbiol. 1984, 3: 210-212. 10.1007/BF02014881.PubMed
56.
Leriche V, Sibille P, Carpentier B: Use of an enzyme-linked lectinsorbent assay to monitor the shift in polysaccharide composition in bacterial biofilms. Appl Environ Microbiol. 2000, 66: 1851-1856. 10.1128/AEM.66.5.1851-1856.2000.PubMedPubMedCentral
57.
Thomas VL, Sanford BA, Moreno R, Ramsay MA: Enzyme-linked lectinsorbent assay measures N-acetyl-D-glucosamine in matrix of biofilm produced by Staphylococcus epidermidis. Curr Microbiol. 1997, 35: 249-254. 10.1007/s002849900248.PubMed
58.
Parker N, Makin CA, Ching CK, Eccleston D, Taylor OM, Milton JD, Rhodes JM: A new enzyme-linked lectin/mucin antibody sandwich assay (CAM 17.1/WGA) assessed in combination with CA 19-9 and peanut lectin binding assay for the diagnosis of pancreatic cancer. Cancer. 1992, 70: 1062-1068. 10.1002/1097-0142(19920901)70:5<1062::AID-CNCR2820700509>3.0.CO;2-P.PubMed
59.
Gornik O, Lauc G: Enzyme linked lectin assay (ELLA) for direct analysis of transferrin sialylation in serum samples. Clin Biochem. 2007, 40: 718-723. 10.1016/j.clinbiochem.2007.01.010.PubMed
60.
Dwek MV, Jenks A, Leathem AJ: A sensitive assay to measure biomarker glycosylation demonstrates increased fucosylation of prostate specific antigen (PSA) in patients with prostate cancer compared with benign prostatic hyperplasia. Clin Chim Acta. 2010, 411: 1935-1939. 10.1016/j.cca.2010.08.009.PubMed
61.
Kim HJ, Lee SJ: Antibody-based enzyme-linked lectin assay (ABELLA) for the sialylated recombinant human erythropoietin present in culture supernatant. J Pharm Biomed Anal. 2008, 48: 716-721. 10.1016/j.jpba.2008.07.004.PubMed
62.
Cook DB, Bustamam AA, Brotherick I, Shenton BK, Self CH: Lectin ELISA for the c-erb-B2 tumor marker protein p185 in patients with breast cancer and controls. Clin Chem. 1999, 45: 292-295.PubMed
63.
Matsumoto H, Shinzaki S, Narisada M, Kawamoto S, Kuwamoto K, Moriwaki K, Kanke F, Satomura S, Kumada T, Miyoshi E: Clinical application of a lectin-antibody ELISA to measure fucosylated haptoglobin in sera of patients with pancreatic cancer. Clin Chem Lab Med. 2010, 48: 505-512.PubMed
64.
Chen S, Haab BB: Analysis of glycans on serum proteins using antibody microarrays. Methods Mol Biol. 2009, 520: 39-58. 10.1007/978-1-60327-811-9_4.PubMedPubMedCentral
65.
Li C, Lubman DM: Analysis of serum protein glycosylation with antibody-lectin microarray for high-throughput biomarker screening. Methods Mol Biol. 2011, 723: 15-28. 10.1007/978-1-61779-043-0_2.PubMed
66.
Thompson R, Creavin A, O'Connell M, O'Connor B, Clarke P: Optimization of the enzyme-linked lectin assay for enhanced glycoprotein and glycoconjugate analysis. Anal Biochem. 2011, 413: 114-122. 10.1016/j.ab.2011.02.013.PubMed
67.
Meany DL, Sokoll LJ, Chan DW: Early Detection of Cancer: Immunoassays for Plasma Tumor Markers. Expert Opin Med Diagn. 2009, 3: 597-605. 10.1517/17530050903266830.PubMedPubMedCentral
68.
Yoshida S, Kurokohchi K, Arima K, Masaki T, Hosomi N, Funaki T, Murota M, Kita Y, Watanabe S, Kuriyama S: Clinical significance of lens culinaris agglutinin-reactive fraction of serum alpha-fetoprotein in patients with hepatocellular carcinoma. Int J Oncol. 2002, 20: 305-309.PubMed
69.
Johnson PJ, Poon TC, Hjelm NM, Ho CS, Ho SK, Welby C, Stevenson D, Patel T, Parekh R, Townsend RR: Glycan composition of serum alpha-fetoprotein in patients with hepatocellular carcinoma and non-seminomatous germ cell tumour. Br J Cancer. 1999, 81: 1188-1195. 10.1038/sj.bjc.6690828.PubMedPubMedCentral
70.
Nakagawa T, Miyoshi E, Yakushijin T, Hiramatsu N, Igura T, Hayashi N, Taniguchi N, Kondo A: Glycomic analysis of alpha-fetoprotein L3 in hepatoma cell lines and hepatocellular carcinoma patients. J Proteome Res. 2008, 7: 2222-2233. 10.1021/pr700841q.PubMed
71.
Haab BB, Yue T: High-throughput studies of protein glycoforms using antibody-lectin sandwich arrays. Methods Mol Biol. 2011, 785: 223-236. 10.1007/978-1-61779-286-1_15.PubMedPubMedCentral
72.
Katrlik J, Svitel J, Gemeiner P, Kozar T, Tkac J: Glycan and lectin microarrays for glycomics and medicinal applications. Med Res Rev. 2010, 30: 394-418.PubMed
73.
Patwa T, Li C, Simeone DM, Lubman DM: Glycoprotein analysis using protein microarrays and mass spectrometry. Mass Spectrom Rev. 2010, 29: 830-844. 10.1002/mas.20269.PubMedPubMedCentral
74.
Haab BB, Porter A, Yue T, Li L, Scheiman J, Anderson MA, Barnes D, Schmidt CM, Feng Z, Simeone DM: Glycosylation variants of mucins and CEACAMs as candidate biomarkers for the diagnosis of pancreatic cystic neoplasms. Ann Surg. 2010, 251: 937-945. 10.1097/SLA.0b013e3181d7738d.PubMedPubMedCentral
75.
Li C, Simeone DM, Brenner DE, Anderson MA, Shedden KA, Ruffin MT, Lubman DM: Pancreatic cancer serum detection using a lectin/glyco-antibody array method. J Proteome Res. 2009, 8: 483-492. 10.1021/pr8007013.PubMedPubMedCentral
76.
Yue T, Goldstein IJ, Hollingsworth MA, Kaul K, Brand RE, Haab BB: The prevalence and nature of glycan alterations on specific proteins in pancreatic cancer patients revealed using antibody-lectin sandwich arrays. Mol Cell Proteomics. 2009, 8: 1697-1707. 10.1074/mcp.M900135-MCP200.PubMedPubMedCentral
77.
78.
Meany DL, Zhang Z, Sokoll LJ, Zhang H, Chan DW: Glycoproteomics for prostate cancer detection: changes in serum PSA glycosylation patterns. J Proteome Res. 2009, 8: 613-619. 10.1021/pr8007539.PubMedPubMedCentral
79.
Arnold JN, Saldova R, Galligan MC, Murphy TB, Mimura-Kimura Y, Telford JE, Godwin AK, Rudd PM: Novel glycan biomarkers for the detection of lung cancer. J Proteome Res. 2011, 10: 1755-1764. 10.1021/pr101034t.PubMed
80.
Bones J, Mittermayr S, O'Donoghue N, Guttman A, Rudd PM: Ultra performance liquid chromatographic profiling of serum N-glycans for fast and efficient identification of cancer associated alterations in glycosylation. Anal Chem. 2010, 82: 10208-10215. 10.1021/ac102860w.PubMed
81.
Zauner G, Koeleman CA, Deelder AM, Wuhrer M: Protein glycosylation analysis by HILIC-LC-MS of proteinase K-generated N- and O-glycopeptides. J Sep Sci. 2010, 33: 903-910. 10.1002/jssc.200900850.PubMed
82.
Li B, An HJ, Kirmiz C, Lebrilla CB, Lam KS, Miyamoto S: Glycoproteomic analyses of ovarian cancer cell lines and sera from ovarian cancer patients show distinct glycosylation changes in individual proteins. J Proteome Res. 2008, 7: 3776-3788. 10.1021/pr800297u.PubMed
83.
Ruhaak LR, Miyamoto S, Kelly K, Lebrilla CB: N-Glycan profiling of dried blood spots. Anal Chem. 2012, 84: 396-402. 10.1021/ac202775t.PubMed
84.
Alley WR, Madera M, Mechref Y, Novotny MV: Chip-based reversed-phase liquid chromatography-mass spectrometry of permethylated N-linked glycans: a potential methodology for cancer-biomarker discovery. Anal Chem. 2011, 82: 5095-5106.
85.
Mechref Y: Analysis of glycans derived from glycoconjugates by capillary electrophoresis-mass spectrometry. Electrophoresis. 2011, 32: 3467-3481. 10.1002/elps.201100342.PubMedPubMedCentral
86.
Kita Y, Miura Y, Furukawa J, Nakano M, Shinohara Y, Ohno M, Takimoto A, Nishimura S: Quantitative glycomics of human whole serum glycoproteins based on the standardized protocol for liberating N-glycans. Mol Cell Proteomics. 2007, 6: 1437-1445. 10.1074/mcp.T600063-MCP200.PubMed
87.
Kyselova Z, Mechref Y, Kang P, Goetz JA, Dobrolecki LE, Sledge GW, Schnaper L, Hickey RJ, Malkas LH, Novotny MV: Breast cancer diagnosis and prognosis through quantitative measurements of serum glycan profiles. Clin Chem. 2008, 54: 1166-1175. 10.1373/clinchem.2007.087148.PubMed
88.
Imre T, Kremmer T, Heberger K, Molnar-Szollosi E, Ludanyi K, Pocsfalvi G, Malorni A, Drahos L, Vekey K: Mass spectrometric and linear discriminant analysis of N-glycans of human serum alpha-1-acid glycoprotein in cancer patients and healthy individuals. J Proteomics. 2008, 71: 186-197. 10.1016/j.jprot.2008.04.005.PubMed
89.
Tsai HY, Boonyapranai K, Sriyam S, Yu CJ, Wu SW, Khoo KH, Phutrakul S, Chen ST: Glycoproteomics analysis to identify a glycoform on haptoglobin associated with lung cancer. Proteomics. 2011, 11: 2162-2170. 10.1002/pmic.201000319.PubMed
90.
Zhang S, Shu H, Luo K, Kang X, Zhang Y, Lu H, Liu Y: N-linked glycan changes of serum haptoglobin beta chain in liver disease patients. Mol Biosyst. 2011, 7: 1621-1628. 10.1039/c1mb05020f.PubMed
91.
Drabovich AP, Diamandis EP: Combinatorial peptide libraries facilitate development of multiple reaction monitoring assays for low-abundance proteins. J Proteome Res. 2010, 9: 1236-1245. 10.1021/pr900729g.PubMed
92.
Keshishian H, Addona T, Burgess M, Kuhn E, Carr SA: Quantitative, multiplexed assays for low abundance proteins in plasma by targeted mass spectrometry and stable isotope dilution. Mol Cell Proteomics. 2007, 6: 2212-2229. 10.1074/mcp.M700354-MCP200.PubMedPubMedCentral
93.
Keshishian H, Addona T, Burgess M, Mani DR, Shi X, Kuhn E, Sabatine MS, Gerszten RE, Carr SA: Quantification of cardiovascular biomarkers in patient plasma by targeted mass spectrometry and stable isotope dilution. Mol Cell Proteomics. 2009, 8: 2339-2349. 10.1074/mcp.M900140-MCP200.PubMedPubMedCentral
94.
Kulasingam V, Smith CR, Batruch I, Buckler A, Jeffery DA, Diamandis EP: "Product ion monitoring" assay for prostate-specific antigen in serum using a linear ion-trap. J Proteome Res. 2008, 7: 640-647. 10.1021/pr7005999.PubMed
95.
Anderson NL, Anderson NG, Haines LR, Hardie DB, Olafson RW, Pearson TW: Mass spectrometric quantitation of peptides and proteins using stable isotope standards and capture by anti-peptide antibodies (SISCAPA). J Proteome Res. 2004, 3: 235-244. 10.1021/pr034086h.PubMed
96.
Anderson NL, Jackson A, Smith D, Hardie D, Borchers C, Pearson TW: SISCAPA peptide enrichment on magnetic beads using an in-line bead trap device. Mol Cell Proteomics. 2009, 8: 995-1005. 10.1074/mcp.M800446-MCP200.PubMedPubMedCentral
97.
Kulasingam V, Smith CR, Batruch I, Diamandis EP: Immuno-mass spectrometry: quantification of low-abundance proteins in biological fluids. Methods Mol Biol. 2011, 728: 207-218. 10.1007/978-1-61779-068-3_13.PubMed
98.
Whiteaker JR, Zhao L, Anderson L, Paulovich AG: An automated and multiplexed method for high throughput peptide immunoaffinity enrichment and multiple reaction monitoring mass spectrometry-based quantification of protein biomarkers. Mol Cell Proteomics. 2010, 9: 184-196. 10.1074/mcp.M900254-MCP200.PubMed
99.
Zhao L, Whiteaker JR, Pope ME, Kuhn E, Jackson A, Anderson NL, Pearson TW, Carr SA, Paulovich AG: Quantification of proteins using peptide immunoaffinity enrichment coupled with mass spectrometry. J Vis Exp. 2011
100.
Ahn YH, Kim YS, Ji ES, Lee JY, Jung JA, Ko JH, Yoo JS: Comparative quantitation of aberrant glycoforms by lectin-based glycoprotein enrichment coupled with multiple-reaction monitoring mass spectrometry. Anal Chem. 2010, 82: 4441-4447. 10.1021/ac1001965.PubMed
101.
Ahn YH, Lee JY, Kim YS, Ko JH, Yoo JS: Quantitative analysis of an aberrant glycoform of TIMP1 from colon cancer serum by L-PHA-enrichment and SISCAPA with MRM mass spectrometry. J Proteome Res. 2009, 8: 4216-4224. 10.1021/pr900269s.PubMed
102.
Ahn YH, Shin PM, Oh NR, Park GW, Kim H, Yoo JS: A lectin-coupled, targeted proteomic mass spectrometry (MRM MS) platform for identification of multiple liver cancer biomarkers in human plasma. J Proteomics. 2012, 75: 5507-5515. 10.1016/j.jprot.2012.06.027.PubMed
103.
Li Y, Tian Y, Rezai T, Prakash A, Lopez MF, Chan DW, Zhang H: Simultaneous analysis of glycosylated and sialylated prostate-specific antigen revealing differential distribution of glycosylated prostate-specific antigen isoforms in prostate cancer tissues. Anal Chem. 2011, 83: 240-245. 10.1021/ac102319g.PubMed
104.
Song E, Pyreddy S, Mechref Y: Quantification of glycopeptides by multiple reaction monitoring liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. 2012, 26: 1941-1954. 10.1002/rcm.6290.PubMedPubMedCentral
105.
Wada Y, Azadi P, Costello CE, Dell A, Dwek RA, Geyer H, Geyer R, Kakehi K, Karlsson NG, Kato K, Kawasaki N, Khoo KH, Kim S, Kondo A, Lattova E, Mechref Y, Miyoshi E, Nakamura K, Narimatsu H, Novotny MV, Packer NH, Perreault H, Peter-Katalinic J, Pohlentz G, Reinhold VN, Rudd PM, Suzuki A, Taniguchi N: Comparison of the methods for profiling glycoprotein glycans--HUPO Human Disease Glycomics/Proteome Initiative multi-institutional study. Glycobiology. 2007, 17: 411-422. 10.1093/glycob/cwl086.PubMed
106.
Chen R, Jiang X, Sun D, Han G, Wang F, Ye M, Wang L, Zou H: Glycoproteomics analysis of human liver tissue by combination of multiple enzyme digestion and hydrazide chemistry. J Proteome Res. 2009, 8: 651-661. 10.1021/pr8008012.PubMed
107.
Cutalo JM, Deterding LJ, Tomer KB: Characterization of glycopeptides from HIV-I(SF2) gp120 by liquid chromatography mass spectrometry. J Am Soc Mass Spectrom. 2004, 15: 1545-1555. 10.1016/j.jasms.2004.07.008.PubMedPubMedCentral
108.
Leymarie N, Zaia J: Effective use of mass spectrometry for glycan and glycopeptide structural analysis. Anal Chem. 2012, 84: 3040-3048. 10.1021/ac3000573.PubMedPubMedCentral
109.
Kurogochi M, Matsushista T, Amano M, Furukawa J, Shinohara Y, Aoshima M, Nishimura S: Sialic acid-focused quantitative mouse serum glycoproteomics by multiple reaction monitoring assay. Mol Cell Proteomics. 2010, 9: 2354-2368. 10.1074/mcp.M110.000430.PubMedPubMedCentral
110.
Rebecchi KR, Wenke JL, Go EP, Desaire H: Label-free quantitation: a new glycoproteomics approach. J Am Soc Mass Spectrom. 2009, 20: 1048-1059. 10.1016/j.jasms.2009.01.013.PubMed
111.
Maresca B, Cigliano L, Corsaro MM, Pieretti G, Natale M, Bucci EM, Dal Piaz F, Balato N, Nino M, Ayala F, Abrescia P: Quantitative determination of haptoglobin glycoform variants in psoriasis. Biol Chem. 2010, 391: 1429-1439.PubMed
112.
Nakano M, Nakagawa T, Ito T, Kitada T, Hijioka T, Kasahara A, Tajiri M, Wada Y, Taniguchi N, Miyoshi E: Site-specific analysis of N-glycans on haptoglobin in sera of patients with pancreatic cancer: a novel approach for the development of tumor markers. Int J Cancer. 2008, 122: 2301-2309. 10.1002/ijc.23364.PubMed
113.
Ivancic MM, Gadgil HS, Halsall HB, Treuheit MJ: LC/MS analysis of complex multiglycosylated human alpha(1)-acid glycoprotein as a model for developing identification and quantitation methods for intact glycopeptide analysis. Anal Biochem. 2010, 400: 25-32. 10.1016/j.ab.2010.01.026.PubMed
114.
Zhao Y, Jia W, Wang J, Ying W, Zhang Y, Qian X: Fragmentation and site-specific quantification of core fucosylated glycoprotein by multiple reaction monitoring-mass spectrometry. Anal Chem. 2011, 83: 8802-8809. 10.1021/ac201676a.PubMed
115.
Lopez MF, Rezai T, Sarracino DA, Prakash A, Krastins B, Athanas M, Singh RJ, Barnidge DR, Oran P, Borges C, Nelson RW: Selected reaction monitoring-mass spectrometric immunoassay responsive to parathyroid hormone and related variants. Clin Chem. 2010, 56: 281-290. 10.1373/clinchem.2009.137323.PubMed
116.
Hua S, Lebrilla C, An HJ: Application of nano-LC-based glycomics towards biomarker discovery. Bioanalysis. 2011, 3: 2573-2585. 10.4155/bio.11.263.PubMed
117.
Ikegami T, Tomomatsu K, Takubo H, Horie K, Tanaka N: Separation efficiencies in hydrophilic interaction chromatography. J Chromatogr A. 2008, 1184: 474-503. 10.1016/j.chroma.2008.01.075.PubMed
118.
Zauner G, Deelder AM, Wuhrer M: Recent advances in hydrophilic interaction liquid chromatography (HILIC) for structural glycomics. Electrophoresis. 2011, 32: 3456-3466. 10.1002/elps.201100247.PubMed
119.
Manimala JC, Li Z, Jain A, VedBrat S, Gildersleeve JC: Carbohydrate array analysis of anti-Tn antibodies and lectins reveals unexpected specificities: implications for diagnostic and vaccine development. Chembiochem. 2005, 6: 2229-2241. 10.1002/cbic.200500165.PubMed
120.
Manimala JC, Roach TA, Li Z, Gildersleeve JC: High-throughput carbohydrate microarray profiling of 27 antibodies demonstrates widespread specificity problems. Glycobiology. 2007, 17: 17C-23C. 10.1093/glycob/cwm047.PubMed
121.
Magnani JL, Nilsson B, Brockhaus M, Zopf D, Steplewski Z, Koprowski H, Ginsburg V: A monoclonal antibody-defined antigen associated with gastrointestinal cancer is a ganglioside containing sialylated lacto-N-fucopentaose II. J Biol Chem. 1982, 257: 14365-14369.PubMed
122.
Safi F, Schlosser W, Kolb G, Beger HG: Diagnostic value of CA 19-9 in patients with pancreatic cancer and nonspecific gastrointestinal symptoms. J Gastrointest Surg. 1997, 1: 106-112. 10.1016/S1091-255X(97)80097-2.PubMed
123.
Duffy MJ, Evoy D, McDermott EW: CA 15-3: uses and limitation as a biomarker for breast cancer. Clin Chim Acta. 2010, 411: 1869-1874. 10.1016/j.cca.2010.08.039.PubMed
124.
von Mensdorff-Pouilly S, Gourevitch MM, Kenemans P, Verstraeten AA, van Kamp GJ, Kok A, van Uffelen K, Snijdewint FG, Paul MA, Meijer S, Hilgers J: An enzyme-linked immunosorbent assay for the measurement of circulating antibodies to polymorphic epithelial mucin (MUC1). Tumour Biol. 1998, 19: 186-195. 10.1159/000030006.PubMed
125.
Babovic-Vuksanovic D, O'Brien JF: Laboratory diagnosis of congenital disorders of glycosylation type I by analysis of transferrin glycoforms. Mol Diagn Ther. 2007, 11: 303-311. 10.1007/BF03256251.PubMed
126.
Helander A, Bergstrom J, Freeze HH: Testing for congenital disorders of glycosylation by HPLC measurement of serum transferrin glycoforms. Clin Chem. 2004, 50: 954-958. 10.1373/clinchem.2003.029629.PubMed
127.
Kuzmanov U, Smith CR, Batruch I, Soosaipillai A, Diamandis A, Diamandis EP: Separation of kallikrein 6 glycoprotein subpopulations in biological fluids by anion-exchange chromatography coupled to ELISA and identification by mass spectrometry. Proteomics. 2012, 12: 799-809. 10.1002/pmic.201100371.PubMed
128.
Gullfot F, Tan TC, von Schantz L, Karlsson EN, Ohlin M, Brumer H, Divne C: The crystal structure of XG-34, an evolved xyloglucan-specific carbohydrate-binding module. Proteins. 2010, 78: 785-789.PubMed
129.
Gunnarsson LC, Dexlin L, Karlsson EN, Holst O, Ohlin M: Evolution of a carbohydrate binding module into a protein-specific binder. Biomol Eng. 2006, 23: 111-117. 10.1016/j.bioeng.2005.12.002.PubMed
130.
Matsubara T, Iida M, Tsumuraya T, Fujii I, Sato T: Selection of a carbohydrate-binding domain with a helix-loop-helix structure. Biochemistry. 2008, 47: 6745-6751. 10.1021/bi8000837.PubMed
131.
Matsubara T, Sumi M, Kubota H, Taki T, Okahata Y, Sato T: Inhibition of influenza virus infections by sialylgalactose-binding peptides selected from a phage library. J Med Chem. 2009, 52: 4247-4256. 10.1021/jm801570y.PubMed
132.
von Schantz L, Gullfot F, Scheer S, Filonova L, Cicortas Gunnarsson L, Flint JE, Daniel G, Nordberg-Karlsson E, Brumer H, Ohlin M: Affinity maturation generates greatly improved xyloglucan-specific carbohydrate binding modules. BMC Biotechnol. 2009, 9: 92-10.1186/1472-6750-9-92.PubMedPubMedCentral
133.
Boese BJ, Breaker RR: In vitro selection and characterization of cellulose-binding DNA aptamers. Nucleic Acids Res. 2007, 35: 6378-6388. 10.1093/nar/gkm708.PubMedPubMedCentral
134.
Boese BJ, Corbino K, Breaker RR: In vitro selection and characterization of cellulose-binding RNA aptamers using isothermal amplification. Nucleosides Nucleotides Nucleic Acids. 2008, 27: 949-966. 10.1080/15257770802257903.PubMed
135.
Ferreira CS, Cheung MC, Missailidis S, Bisland S, Gariepy J: Phototoxic aptamers selectively enter and kill epithelial cancer cells. Nucleic Acids Res. 2009, 37: 866-876. 10.1093/nar/gkn967.PubMed
136.
Li M, Lin N, Huang Z, Du L, Altier C, Fang H, Wang B: Selecting aptamers for a glycoprotein through the incorporation of the boronic acid moiety. J Am Chem Soc. 2008, 130: 12636-12638. 10.1021/ja801510d.PubMedPubMedCentral
137.
Rose CM, Hayes MJ, Stettler GR, Hickey SF, Axelrod TM, Giustini NP, Suljak SW: Capillary electrophoretic development of aptamers for a glycosylated VEGF peptide fragment. Analyst. 2010, 135: 2945-2951. 10.1039/c0an00445f.PubMedPubMedCentral
138.
Gerlach JQ, Cunningham S, Kane M, Joshi L: Glycobiomimics and glycobiosensors. Biochem Soc Trans. 2010, 38: 1333-1336. 10.1042/BST0381333.PubMed
139.
Jelinek R, Kolusheva S: Carbohydrate biosensors. Chem Rev. 2004, 104: 5987-6015. 10.1021/cr0300284.PubMed
140.
Cheng W, Ding L, Lei J, Ding S, Ju H: Effective cell capture with tetrapeptide-functionalized carbon nanotubes and dual signal amplification for cytosensing and evaluation of cell surface carbohydrate. Anal Chem. 2008, 80: 3867-3872. 10.1021/ac800199t.PubMed
141.
Ding L, Cheng W, Wang X, Ding S, Ju H: Carbohydrate monolayer strategy for electrochemical assay of cell surface carbohydrate. J Am Chem Soc. 2008, 130: 7224-7225. 10.1021/ja801468b.PubMed
142.
La Belle JT, Gerlach JQ, Svarovsky S, Joshi L: Label-free impedimetric detection of glycan-lectin interactions. Anal Chem. 2007, 79: 6959-6964. 10.1021/ac070651e.PubMed
143.
Oliveira MD, Correia MT, Diniz FB: Concanavalin A and polyvinyl butyral use as a potential dengue electrochemical biosensor. Biosens Bioelectron. 2009, 25: 728-732. 10.1016/j.bios.2009.08.009.PubMed
144.
Phillips MD, Fyles TM, Barwell NP, James TD: Carbohydrate sensing using a fluorescent molecular tweezer. Chem Commun (Camb). 2009, 6557-6559.
145.
Dai Z, Kawde AN, Xiang Y, La Belle JT, Gerlach J, Bhavanandan VP, Joshi L, Wang J: Nanoparticle-based sensing of glycan-lectin interactions. J Am Chem Soc. 2006, 128: 10018-10019. 10.1021/ja063565p.PubMed
146.
Pei Z, Anderson H, Aastrup T, Ramstrom O: Study of real-time lectin-carbohydrate interactions on the surface of a quartz crystal microbalance. Biosens Bioelectron. 2005, 21: 60-66. 10.1016/j.bios.2004.10.006.PubMed
147.
Shen Z, Huang M, Xiao C, Zhang Y, Zeng X, Wang PG: Nonlabeled quartz crystal microbalance biosensor for bacterial detection using carbohydrate and lectin recognitions. Anal Chem. 2007, 79: 2312-2319. 10.1021/ac061986j.PubMedPubMedCentral
148.
Astrom E, Ohlson S: Detection of weakly interacting anti-carbohydrate scFv phages using surface plasmon resonance. J Mol Recognit. 2006, 19: 282-286. 10.1002/jmr.786.PubMed
149.
Foley KJ, Forzani ES, Joshi L, Tao N: Detection of lectin-glycan interaction using high resolution surface plasmon resonance. Analyst. 2008, 133: 744-746. 10.1039/b719321a.PubMed
150.
Mercey E, Sadir R, Maillart E, Roget A, Baleux F, Lortat-Jacob H, Livache T: Polypyrrole oligosaccharide array and surface plasmon resonance imaging for the measurement of glycosaminoglycan binding interactions. Anal Chem. 2008, 80: 3476-3482. 10.1021/ac800226k.PubMed
151.
Wu C, Orozco C, Boyer J, Leglise M, Goodale J, Batalov S, Hodge CL, Haase J, Janes J, Huss JW, Su AI: BioGPS: an extensible and customizable portal for querying and organizing gene annotation resources. Genome Biol. 2009, 10: R130-10.1186/gb-2009-10-11-r130.PubMedPubMedCentral
152.
Su AI, Wiltshire T, Batalov S, Lapp H, Ching KA, Block D, Zhang J, Soden R, Hayakawa M, Kreiman G, Cooke MP, Walker JR, Hogenesch JB: A gene atlas of the mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci USA. 2004, 101: 6062-6067. 10.1073/pnas.0400782101.PubMedPubMedCentral
153.
Abelev GI: Production of embryonal alpha-globulin by transplantable mouse hepatomas. Transplantation. 1963, 1: 174-180. 10.1097/00007890-196301020-00004.PubMed
154.
Tumor markers: physiology, pathobiology, technology, and clinical applications. 2002, Washington, DC: AACC Press
155.
Bagshawe KD: Markers in gynaecological cancer. Arch Gynecol. 1980, 229: 303-310. 10.1007/BF02108581.PubMed
156.
Bast RC: Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest. 1981, 68: 1331-1337. 10.1172/JCI110380.PubMedPubMedCentral
157.
Bast RC: 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001, 19: 1865-1878.PubMed
158.
Hilkens J: Monoclonal antibodies against human milk-fat globule membranes detecting differentiation antigens of the mammary gland and its tumors. Int J Cancer. 1984, 34: 197-206. 10.1002/ijc.2910340210.PubMed
159.
Kufe D: Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. Hybridoma. 1984, 3: 223-232. 10.1089/hyb.1984.3.223.PubMed
160.
Koprowski H: Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet. 1979, 5: 957-971. 10.1007/BF01542654.PubMed
161.
Ludwig JA, Weinstein JN: Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer. 2005, 5: 845-856. 10.1038/nrc1739.PubMed
162.
Coussens L: Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science. 1985, 230: 1132-1139. 10.1126/science.2999974.PubMed
163.
Yamamoto T: Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature. 1986, 319: 230-234. 10.1038/319230a0.PubMed
164.
Wang MC: Purification of a human prostate specific antigen. Invest Urol. 1979, 17: 159-163.PubMed
165.
Carayanniotis G, Rao VP: Searching for pathogenic epitopes in thyroglobulin: parameters and caveats. Immunol Today. 1977, 18: 83-88.
166.
Sturgeon C: Practice guidelines for tumor marker use in the clinic. Clin Chem. 2002, 48: 1151-1159.PubMed
167.
Beveridge RA: Review of clinical studies of CA 27.29 in breast cancer management. Int J Biol Markers. 1999, 14: 36-39.PubMed
168.
Kulasingam V, Diamandis EP: Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Nat Clin Pract Oncol. 2008, 5: 588-599.PubMed
Metadata
Title
The sweet and sour of serological glycoprotein tumor biomarker quantification
Authors
Uros Kuzmanov
Hari Kosanam
Eleftherios P Diamandis
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Medicine / Issue 1/2013
Electronic ISSN: 1741-7015
DOI
https://doi.org/10.1186/1741-7015-11-31

Other articles of this Issue 1/2013

BMC Medicine 1/2013 Go to the issue

Research article

16/6-idiotype expressing antibodies induce brain inflammation and cognitive impairment in mice: the mosaic of central nervous system involvement in lupus

Minireview

Bariatric surgery: the challenges with candidate selection, individualizing treatment and clinical outcomes

Research article

Comparing influenza vaccine efficacy against mismatched and matched strains: a systematic review and meta-analysis

Research article

Caregivers’ understanding of dementia predicts patients’ comfort at death: a prospective observational study

Debate

Clinical classification in mental health at the cross-roads: which direction next?

Research article

Collectives of diagnostic biomarkers identify high-risk subpopulations of hematuria patients: exploiting heterogeneity in large-scale biomarker data